IP Library › Granted Patent US 8,652,443
Granted Patent B2
US 8,652,443 · App. 12/371,155 · Granted Feb 18, 2014

Foamable microemulsion compositions for topical administration

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,652,443
App. No.
12/371,155
Granted
Feb 18, 2014
Kind
B2
Abstract

Described are ethanol-free foamable microemulsions for topical application, and method of making them. The propellants used in the compositions may be environmentally-friendly hydrofluoroalkanes. The foam compositions may also comprise one or more of a variety of active ingredients, including anti-inflammatory agents, anesthetics, and keratolytic agents.

Claims (24)

1. A method of locally anesthetizing the skin of a subject, comprising the step of

applying topically to the skin of a subject in need thereof an effective amount of a composition comprising

water, in a quantity from about 15% to about 40% by weight of the composition;

propylene glycol, in a quantity from about 11% to about 18% by weight of the composition;

lidocaine, in a quantity from about 1% to about 6% by weight of the composition;

polysorbate 80, in a quantity from about 32% to about 39% by weight of the composition;

1,1,1,2-tetrafluoroethane, in a quantity from about 5% to about 13% by weight of the composition;

benzalkonium chloride, in a quantity from about 0.008% to about 0.08% by weight of the composition;

benzyl alcohol, in a quantity from about 0.8% to about 3.0% by weight of the composition; and

isopropyl myristate, in a quantity from about 10% to about 35% by weight of the composition;

wherein

the water, the propylene glycol, the lidocaine, the polysorbate 80, the benzalkonium chloride, the benzyl alcohol, and the isopropyl myristate form a microemulsion;

the microemulsion is optically clear and optically isotropic;

the composition is a single phase; and

the composition is optically clear.

2. The method of claim 1 , wherein the composition comprises:

water, in about 20% by weight of the composition;

propylene glycol, in about 14% by weight of the composition;

lidocaine, in about 4.0% by weight of the composition;

polysorbate 80, in about 39% by weight of the composition;

1,1,1,2-tetrafluoroethane, in about 6% by weight of the composition;

benzalkonium chloride, in about 0.04% by weight of the composition;

benzyl alcohol, in about 1.9% by weight of the composition; and

isopropyl myristate, in about 15% by weight of the composition.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY AGREEMENT Recorded Jul 6, 2015
From: ECR PHARMACEUTICALS CO., INC.; PRECISION DERMATOLOGY, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036091/0257 →
RELEASE OF SECURITY INTEREST Recorded Jul 7, 2014
From: GCI CAPITAL MARKETS, LLC
To: PRECISION DERMATOLOGY, INC.
Reel/Frame 033280/0556 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2013
From: MIDCAP FUNDING III, LLC
To: PRECISION DERMATOLOGY COMPANY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN, LLC; PRECISION MD, LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
Reel/Frame 031296/0492 →
SECURITY AGREEMENT Recorded Sep 20, 2013
From: PRECISION DERMATOLOGY, INC.
To: GCI CAPITAL MARKETS LLC
Reel/Frame 031249/0011 →
SECURITY AGREEMENT Recorded May 18, 2012
From: PRECISION DERMATOLOGY, INC.; ONSET DERMATOLOGICS, LLC; PROSKIN LLC; PRECISION MD LLC; TP CREAM SUB, LLC; TP LOTION SUB, LLC
To: MIDCAP FUNDING III, LLC
Reel/Frame 028234/0424 →